For informational and research purposes only. Not medical advice. Content is aggregated from public sources. Always consult a qualified healthcare provider.
Performance & Growth Hormone · Comparison

CJC-1295 + GHRP-6 Stack vs GHRP-2

A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

CJC-1295 + GHRP-6 StackGHRP-2
CategoryPerformance & Growth HormonePerformance & Growth Hormone
Also known asCJC GHRP-6 combination, GH releasing stack, GHRH GHRP combination, CJC-1295 GHRP-6Growth Hormone Releasing Peptide-2, Pralmorelin, KP 102
EvidenceResearch-stagePreclinical only
Dosing rangeCJC-1295 100mcg + GHRP-6 100mcg–CJC-1295 200mcg + GHRP-6 300mcg mcg, 1–3x daily (pre-sleep, pre-workout, morning)100mcg–300mcg mcg, 1–3 times daily, on an empty stomach
AdministrationSubcutaneous injectionSubcutaneous injection, Intramuscular injection
Key side effectsStrong appetite stimulation (GHRP-6 dominant effect), Water retention, Tingling / numbness in extremities, Mild cortisol elevation (GHRP-6 is less selective than ipamorelin)Increased hunger (less than GHRP-6), Elevated cortisol and prolactin at high doses, Water retention, Injection site irritation
Cited sources2 references3 references

Key differences

  • Evidence level differs: CJC-1295 + GHRP-6 Stack is research-stage, while GHRP-2 is preclinical only.
  • Administration: CJC-1295 + GHRP-6 Stack — Subcutaneous injection; GHRP-2 — Subcutaneous injection, Intramuscular injection.
  • Frequency: CJC-1295 + GHRP-6 Stack is typically 1–3x daily (pre-sleep, pre-workout, morning); GHRP-2 is 1–3 times daily, on an empty stomach.
  • Research depth: this profile cites 2 sources for CJC-1295 + GHRP-6 Stack vs 3 for GHRP-2.

How each works

CJC-1295 + GHRP-6 Stack

The GHRH + GHRP combination synergistically amplifies GH pulse amplitude compared to either agent alone. CJC-1295 elevates baseline GH via GHRH receptor signaling at the pituitary; GHRP-6 triggers pulse timing via GHS-R1a. GHRP-6's potent appetite stimulation (significantly stronger than ipamorelin) makes this combination preferred in protocols targeting caloric surplus and mass accumulation.

GHRP-2

GHRP-2 has been extensively studied in both animal and human subjects. Clinical trials have demonstrated significant GH elevation in healthy adults, with a peak GH pulse occurring 15–30 minutes post-injection. Studies show it increases IGF-1 levels with chronic use and may have mild cardioprotective properties. Unlike GHRP-6, it has a lower propensity to stimulate cortisol and prolactin at standard doses.

Read the full CJC-1295 + GHRP-6 Stack profileRead the full GHRP-2 profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.